Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff

Upworthy

14 Jul 2021 0 shares 1 views

Upworthy

Published 14 Jul 2021

As the fallout continues from the FDA’s controversial approval of Biogen’s new Alzheimer’s drug Aduhelm, some insurers are reportedly...

Here’s why three hospitals are refusing to treat patients with Biogen’s new Alzheimer’s drug

The medical community has not been entirely convinced of the U.S. FDA’s decision to approve Biogen Inc’s (NASDAQ: BIIB) Aduhelm..

Invezz 16 Jul 2021

I know I harp a lot on all the ways we structure the market to redistribute income upward, but that’s because we keep digging in..

Eurasia Review 03 Jul 2021